{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:54:17Z","timestamp":1781571257507,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09723-2","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:37:52Z","timestamp":1777426672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2\u2009\u00d7\u20092 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk"],"prefix":"10.1186","volume":"27","author":[{"given":"Phyo Pyae","family":"Nyein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Haskelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Martinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goodman-Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aletta E.","family":"Schutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriobu Chukwudalu","family":"Nnakelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Byakwaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Trevillyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Losso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalingeswaran","family":"Kumarasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Iskandar Shah Raja","family":"Azwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Arnott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nila J.","family":"Dharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1048-6396","authenticated-orcid":false,"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"1","key":"9723_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25219","volume":"22","author":"IY Jung","year":"2019","unstructured":"Jung IY, Rupasinghe D, Woolley I, et al. Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific. J Int AIDS Soc. 2019;22(1):e25219.","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"9723_CR2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100\u201312.","journal-title":"Circulation"},{"issue":"11","key":"9723_CR3","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596\u2013646.","journal-title":"Circulation"},{"key":"9723_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","volume":"239","author":"BG Brenner","year":"2017","unstructured":"Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res. 2017;239:1\u20139.","journal-title":"Virus Res"},{"issue":"1","key":"9723_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","volume":"36","author":"P Cahn","year":"2022","unstructured":"Cahn P, Sierra Madero J, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. AIDS. 2022;36(1):39\u201348.","journal-title":"AIDS"},{"key":"9723_CR6","unstructured":"World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV 2018 [Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-HIV-18.51."},{"key":"9723_CR7","unstructured":"World Health Organization. WHO HIV policy adoption and implementation status in countries, 2023. 2023 [Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/who-hiv-policy-adoption-in-countries_2023.pdf?sfvrsn=e2720212_1#:~:text=A%20total%20of%2099%20countries,of%2099)%20report%20countrywide%20implementation."},{"issue":"7","key":"9723_CR8","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","volume":"9","author":"B Neesgaard","year":"2022","unstructured":"Neesgaard B, Greenberg L, Mir\u00f3 JM, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV. 2022;9(7):e474\u201385.","journal-title":"Lancet HIV"},{"issue":"4","key":"9723_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/QAI.0000000000002357","volume":"84","author":"JA O'Halloran","year":"2020","unstructured":"O\u2019Halloran JA, Sahrmann J, Butler AM, Olsen MA, Powderly WG. Brief report: integrase strand transfer inhibitors are associated with lower risk of incident cardiovascular disease in people living with HIV. J Acquir Immune Defic Syndr. 2020;84(4):396\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9723_CR10","unstructured":"Surial B, Chammartin F, Damas J, et al. Impact of integrase inhibitors on cardiovascular disease events in people with HIV starting antiretroviral therapy. Clin Infect Dis. 2023."},{"issue":"6","key":"9723_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26123","volume":"26","author":"PF Rebeiro","year":"2023","unstructured":"Rebeiro PF, Emond B, Rossi C, et al. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States. J Int AIDS Soc. 2023;26(6):e26123.","journal-title":"J Int AIDS Soc"},{"key":"9723_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101412","volume":"48","author":"S Kanters","year":"2022","unstructured":"Kanters S, Renaud F, Rangaraj A, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. EClinicalMedicine. 2022;48:101412.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"9723_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"9723_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/cid\/ciac827","volume":"76","author":"L Waters","year":"2023","unstructured":"Waters L, Assoumou L, Gonz\u00e1lez-Cord\u00f3n A, et al. Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with human immunodeficiency virus with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial. Clin Infect Dis. 2023;76(5):861\u201370.","journal-title":"Clin Infect Dis"},{"key":"9723_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101836","volume":"57","author":"AT Brennan","year":"2023","unstructured":"Brennan AT, Nattey C, Kileel EM, et al. Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg. South Africa EClinicalMedicine. 2023;57:101836.","journal-title":"South Africa EClinicalMedicine"},{"issue":"8","key":"9723_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/hiv.13273","volume":"23","author":"DM Byonanebye","year":"2022","unstructured":"Byonanebye DM, Polizzotto MN, Neesgaard B, et al. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. HIV Med. 2022;23(8):895\u2013910.","journal-title":"HIV Med"},{"key":"9723_CR17","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2021.39.237.29718","volume":"39","author":"R Musekwa","year":"2021","unstructured":"Musekwa R, Hamooya BM, Koethe JR, Nzala S, Masenga SK. Prevalence and correlates of hypertension in HIV-positive adults from the Livingstone Central Hospital, Zambia. Pan Afr Med J. 2021;39:237.","journal-title":"Pan Afr Med J"},{"key":"9723_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae256","author":"PP Nyein","year":"2024","unstructured":"Nyein PP, Petoumenos K, Borok M, et al. Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae256.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"9723_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","volume":"85","author":"NA Summers","year":"2020","unstructured":"Summers NA, Lahiri CD, Angert CD, et al. Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women. J Acquir Immune Defic Syndr. 2020;85(3):355\u201362.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10254","key":"9723_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"15","key":"9723_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"21","key":"9723_CR22","first-page":"2099","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099.","journal-title":"N Engl J Med"},{"issue":"10","key":"9723_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","volume":"15","author":"A Peikert","year":"2022","unstructured":"Peikert A, Martinez FA, Vaduganathan M, et al. Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER Trial. Circ Heart Fail. 2022;15(10):e010080.","journal-title":"Circ Heart Fail"},{"issue":"24","key":"9723_CR24","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"11","key":"9723_CR25","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1080\/03007995.2022.2115775","volume":"38","author":"B Abiri","year":"2022","unstructured":"Abiri B, Ramezani Ahmadi A, Ebadinejad A, Hosseinpanah F, Valizadeh M. Effects of sodium-glucose co-transporter-2 inhibitors on anthropometric indices and metabolic markers in overweight\/obese individuals without diabetes: a systematic review and meta-analysis. Curr Med Res Opin. 2022;38(11):1853\u201363.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"9723_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12933-022-01574-w","volume":"21","author":"M Li","year":"2022","unstructured":"Li M, Yi T, Fan F, et al. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):139.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"9723_CR27","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.7150\/thno.75121","volume":"12","author":"L Ma","year":"2022","unstructured":"Ma L, Zou R, Shi W, et al. SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia\/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways. Theranostics. 2022;12(11):5034\u201350.","journal-title":"Theranostics"},{"key":"9723_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22528 patients. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.116.004007.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"9723_CR29","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1097\/HJH.0000000000003280","volume":"40","author":"YH Teo","year":"2022","unstructured":"Teo YH, Chia AZQ, Teo YN, et al. The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials. J Hypertens. 2022;40(12):2353\u201372.","journal-title":"J Hypertens"},{"issue":"5","key":"9723_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019463","volume":"10","author":"YH Teo","year":"2021","unstructured":"Teo YH, Teo YN, Syn NL, et al. Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021;10(5):e019463.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"9723_CR31","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1097\/HJH.0000000000002480","volume":"38","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Smits MM, Ruiter D, et al. Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. J Hypertens. 2020;38(9):1811\u20139.","journal-title":"J Hypertens"},{"issue":"2","key":"9723_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2025.105040","volume":"55","author":"V Guiraud","year":"2025","unstructured":"Guiraud V, Sauce D, Bittar R, et al. Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIV. Infect Dis Now. 2025;55(2):105040.","journal-title":"Infect Dis Now"},{"issue":"8","key":"9723_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687\u201399.","journal-title":"N Engl J Med"},{"key":"9723_CR34","unstructured":"Recommendations for the use of statin therapy as primary prevention of atherosclerotic cardiovascular disease in people with HIV: The U.S. Department of Health and Human Services (HHS) panel for the use of antiretroviral agents in adults and adolescents with HIV; 2024. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/statin-therapy-adult-adolescent-arv.pdf. Cited 2025 July 21."},{"issue":"12","key":"9723_CR35","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.5551\/jat.29264","volume":"22","author":"M Abe","year":"2015","unstructured":"Abe M, Maruyama N, Maruyama T, Okada K, Soma M. A trial of pitavastatin versus rosuvastatin for dyslipidemia in chronic kidney disease. J Atheroscler Thromb. 2015;22(12):1235\u201347.","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"9723_CR36","first-page":"228","volume":"27","author":"J Cosin Sales","year":"2015","unstructured":"Cosin Sales J, Fuentes Jim\u00e9nez FJ, Mantilla Morat\u00f3 T, et al. Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain. Clin Investig Arterioscler. 2015;27(5):228\u201338.","journal-title":"Clin Investig Arterioscler"},{"key":"9723_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-015-0054-x","volume":"14","author":"R Saeedi","year":"2015","unstructured":"Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G. Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 2015;14:57.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"9723_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1089\/apc.2007.0206","volume":"22","author":"M van den Berg-Wolf","year":"2008","unstructured":"van den Berg-Wolf M, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS. 2008;22(6):483\u20138.","journal-title":"AIDS Patient Care STDS"},{"issue":"8","key":"9723_CR39","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1185\/030079904125004213","volume":"20","author":"T Kosoglou","year":"2004","unstructured":"Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004;20(8):1185\u201395.","journal-title":"Curr Med Res Opin"},{"key":"9723_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082150","author":"W Masson","year":"2021","unstructured":"Masson W, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-inhibitors on epicardial adipose tissue: a meta-analysis. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10082150.","journal-title":"Cells"},{"key":"9723_CR41","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.25","volume":"9","author":"MT Oduah","year":"2023","unstructured":"Oduah MT, Sundaram V, Reddy YN. Epicardial fat in heart failure with preserved ejection fraction: bad actor or just lying around? Card Fail Rev. 2023;9:e06.","journal-title":"Card Fail Rev"},{"issue":"1","key":"9723_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"9723_CR43","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/QAD.0000000000003204","volume":"36","author":"M Tumkosit","year":"2022","unstructured":"Tumkosit M, Han WM, Tankittiwat K, et al. Higher epicardial fat in older adults living with HIV with viral suppression and relationship with liver steatosis, coronary calcium and cardiometabolic risks. AIDS. 2022;36(8):1073\u201381.","journal-title":"AIDS"},{"issue":"1","key":"9723_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01228-3","volume":"20","author":"S Hiruma","year":"2021","unstructured":"Hiruma S, Shigiyama F, Hisatake S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20(1):32.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"9723_CR45","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22798","volume":"28","author":"G Iacobellis","year":"2020","unstructured":"Iacobellis G, Gra-Menendez S. Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity. Obesity Silver Spring. 2020;28(6):1068\u201374.","journal-title":"Obesity Silver Spring"},{"issue":"25","key":"9723_CR46","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"8","key":"9723_CR47","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1249\/01.MSS.0000078923.96621.1D","volume":"35","author":"DR Bassett Jr.","year":"2003","unstructured":"Bassett DR Jr. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1396.","journal-title":"Med Sci Sports Exerc"},{"issue":"25 Pt B","key":"9723_CR48","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr.","year":"2014","unstructured":"Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935\u201359.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"9723_CR49","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S2352-3018(24)00089-4","volume":"11","author":"D2EFT study group","year":"2024","unstructured":"D2EFT study group. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D(2)EFT): an open-label, randomised, phase 3b\/4 trial. Lancet HIV. 2024;11(7):e436\u201348.","journal-title":"Lancet HIV"},{"issue":"9635","key":"9723_CR50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","volume":"372","author":"Antiretroviral Therapy Cohort Collaboration","year":"2008","unstructured":"Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293\u20139.","journal-title":"Lancet"},{"issue":"6","key":"9723_CR51","doi-asserted-by":"publisher","first-page":"e2114923","DOI":"10.1001\/jamanetworkopen.2021.14923","volume":"4","author":"U Hoffmann","year":"2021","unstructured":"Hoffmann U, Lu MT, Foldyna B, et al. Assessment of coronary artery disease with computed tomography angiography and inflammatory and immune activation biomarkers among adults with hiv eligible for primary cardiovascular prevention. JAMA Netw Open. 2021;4(6):e2114923.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"9723_CR52","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/infdis\/jiu594","volume":"211","author":"RA McKibben","year":"2015","unstructured":"McKibben RA, Margolick JB, Grinspoon S, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis. 2015;211(8):1219\u201328.","journal-title":"J Infect Dis"},{"key":"9723_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00328-4","author":"DM Byonanebye","year":"2024","unstructured":"Byonanebye DM, Polizzotto MN, Maltez F, et al. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts. Lancet HIV. 2024. https:\/\/doi.org\/10.1016\/S2352-3018(23)00328-4.","journal-title":"Lancet HIV"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09723-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09723-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09723-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:12:39Z","timestamp":1781568759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09723-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9723"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09723-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7648678\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The OPTIMAR protocol (v1.0, 03 Jul 2024) is approved by the UNSW Sydney Human Research Ethics Committee (iRECS6294). Every clinical site must receive local IRB\/IEC approval before enrolment. Written, informed consent will be obtained from all participants prior to any study procedure; participants may withdraw their consent at any time without consequence.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"We are willing to provide a model consent form and other related documentation on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"MM has participated in advisory boards for Abbvie and is supported by NHMRC (Investigator Grant. ADK has received funding for advisory board membership for Merck. ADK is a board member Scientia Clinical Research. This is non-remunerated. AES has received speaker honoraria from Servier, Abbott, Sanofi, AstraZeneca, Medtronic, Omron, and Aktiia and serves on scientific advisory boards for Medtronic, Roche\/Alnylam, AstraZeneca, Servier, SiSU Health and Sky Labs. JMT\u2019s institution has received funding for speaking responsibility and advisory board membership for ViiV, Gilead, Moderna and CSL. CA has received honoraria or sat on Advisory Boards\/Steering Committees for Novo Nordisk and Astra Zeneca NJD has received funding from Gilead Sciences Pty Ltd for an unrelated project. Other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"445"}}